Accepting of new medicines registration applications, new site registration applications & formulation approval applications

All local manufacturers and marketing authorization holders of medicine are hereby informed that NMRA has decided to temporary stop accepting new medicines applications, new site master files, formulation applications and new foreign site registration applications from published date of this notice to 1st of February, 2024.

However, new medicines applications, which are having less than five registered products in NMRA will be accepted as per the routine procedures and proceeded on priority basis. New foreign site registration applications on site transfers of already approved sites in NMRA will proceed as per the routine procedures.

(Date: 21 December 2023)